Kufika Kwatsopano 4-Biphenylcarboxylic Acid (92-92-2)

Ndi maulamuliro athu apamwamba, luso lamphamvu komanso njira zogwirira ntchito zapamwamba kwambiri, timapitiliza kupatsa ogula athu zinthu zabwino zodalirika, mitengo yogulitsira yabwino komanso ntchito zabwino kwambiri.Tikufuna kukhala m'modzi mwama bwenzi omwe ali ndi udindo komanso kupindula ndi Newly Arrival 4-Biphenylcarboxylic Acid (92-92-2), Mfundo ya kampani yathu nthawi zonse ndikupereka malonda apamwamba, ntchito zaukadaulo, komanso kulankhulana moona mtima. .Landirani anzanu onse kuti muyesetse kupanga mabizinesi anthawi yayitali.
Ndi maulamuliro athu apamwamba, luso lamphamvu komanso njira zogwirira ntchito zapamwamba kwambiri, timapitiliza kupatsa ogula athu zinthu zabwino zodalirika, mitengo yogulitsira yabwino komanso ntchito zabwino kwambiri.Tikufuna kukhala m'modzi mwama bwenzi omwe ali ndi udindo komanso kupindula nawoChina Organic Synthesis Intermediates, Zogulitsa zathu zimatumizidwa ku Southeast Asia, Middle East, North America ndi Europe.Ubwino wathu ndi wotsimikizika.Ngati muli ndi chidwi ndi chilichonse mwazinthu zathu kapena mukufuna kukambirana za dongosolo lachikhalidwe, onetsetsani kuti mwamasuka kutilumikizana nafe.Tikuyembekezera kupanga ubale wabwino wamabizinesi ndi makasitomala atsopano padziko lonse lapansi posachedwa.

2'-hydroxy-3'-nitro-3-biphenylcarboxylic acid amagwiritsidwa ntchito ngati wapakatikati wa Eltrombopag.
Eltrombopag, yopangidwa ndi GlaxoSmithKline (GSK) ku UK ndipo pambuyo pake idapangidwa limodzi ndi Novartis ku Switzerland, ndiye woyamba komanso wovomerezeka wa agonist ang'onoang'ono omwe si peptide TPO receptor agonist padziko lapansi.Eltrombopag idavomerezedwa ndi US FDA mu 2008 pochiza idiopathic thrombocytopenic purpura (ITP), komanso mu 2014 pochiza aplastic anemia (AA).Ndiwonso mankhwala oyamba ovomerezedwa ndi US FDA pochiza AA m'zaka 30 zaposachedwa.
Mu december2012, US FDA inavomereza Eltrombopag zochizira thrombocytopenia odwala matenda a chiwindi C (CHC), kuti odwala matenda a chiwindi C ndi osauka matenda chifukwa otsika kupatsidwa zinthu za m`mwazi kuwerenga akhoza kuyamba ndi kusunga interferon zochokera muyezo mankhwala kwa matenda a chiwindi.Pa february3, 2014, GlaxoSmithKline adalengeza kuti FDA idapereka chithandizo chamankhwala chopambana cha Eltrombopag pochiza hemopenia kwa odwala omwe ali ndi chemicalbook aplastic anemia (SAA) omwe sanayankhe mokwanira ku immunotherapy.Pa Ogasiti 24, 2015, US FDA idavomereza Eltrombopag kuti azichiza thrombocytopenia mwa akulu ndi ana azaka za 1 ndi kupitilira omwe ali ndi matenda osachiritsika a immune thrombocytopenia (ITP) omwe alibe yankho lokwanira ku corticosteroids, immunoglobulins kapena splenectomy.Pa january4, 2018, Eltrombopag idavomerezedwa kuti ilembedwe ku China kuti ichiritse primary immune thrombocytopenia (ITP).

Ndi maulamuliro athu apamwamba, luso lamphamvu komanso njira zogwirira ntchito zapamwamba kwambiri, timapitiliza kupatsa ogula athu zinthu zabwino zodalirika, mitengo yogulitsira yabwino komanso ntchito zabwino kwambiri.Tikufuna kukhala m'modzi mwama bwenzi omwe ali ndi udindo komanso kupindula ndi Newly Arrival 4-Biphenylcarboxylic Acid (92-92-2), Mfundo ya kampani yathu nthawi zonse ndikupereka malonda apamwamba, ntchito zaukadaulo, komanso kulankhulana moona mtima. .Landirani anzanu onse kuti muyesetse kupanga mabizinesi anthawi yayitali.
Kufika KwatsopanoChina Organic Synthesis Intermediates, Zogulitsa zathu zimatumizidwa ku Southeast Asia, Middle East, North America ndi Europe.Ubwino wathu ndi wotsimikizika.Ngati muli ndi chidwi ndi chilichonse mwazinthu zathu kapena mukufuna kukambirana za dongosolo lachikhalidwe, onetsetsani kuti mwamasuka kutilumikizana nafe.Tikuyembekezera kupanga ubale wabwino wamabizinesi ndi makasitomala atsopano padziko lonse lapansi posachedwa.